Hepatitis B: 50 years after the discovery of Australia antigen

Journal of Viral Hepatitis

Volumn 23, Issue 1, 2016, Pages 5-14

  Suk Fong Lok, A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

antiviral treatment; cirrhosis; hepatitis B surface antigen; hepatocellular carcinoma; vaccine

Indexed keywords

ADEFOVIR DIPIVOXIL; CORTICOSTEROID; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; HEPATITIS B, CHRONIC; HISTORY; IMMUNOLOGY; LIVER; LIVER NEOPLASMS; PATHOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIVER; LIVER NEOPLASMS;

EID: 84954077942     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12444     Document Type: Review

References (97)

1. Sherlock S,. Acute viral hepatitis. Diseases of the Liver and Biliary System, 1st edn. Oxford, UK: Alden Press, 1955: 242-275
2. Blumberg BS, Alter HJ, Visnich S,. A "New" antigen in Leukemia Sera. JAMA 1965; 191: 541-546
3. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI,. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Int Med 1967; 66 (5): 924-931
4. Sutnick AI, London WT, Gerstley BJ, Cronlund MM, Blumberg BS,. Anicteric hepatitis associated with Australia antigen. Occurrence in patients with Down's syndrome. JAMA 1968; 205 (10): 670-674
5. London WT, Sutnick AI, Blumberg BS,. Australia antigen and acute viral hepatitis. Ann Int Med 1969; 70 (1): 55-59
6. Alter HJ, Holland PV, Purcell RH,. The emerging pattern of post-transfusion hepatitis. Am J Med Sci 1975; 270 (2): 329-334
7. Senior JR, Sutnick AI, Goeser E, London WT, Dahlke MB, Blumberg BS,. Reduction of post-transfusion hepatitis by exclusion of Australia antigen from donor blood in an urban public hospital. Am J Med Sci 1974; 267 (3): 171-177
8. Stramer SL, Notari EP, Krysztof DE, Dodd RY,. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion 2013; 53 (10 Pt 2): 2449-2458
9. Dane DS, Cameron CH, Briggs M,. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1 (7649): 695-698
10. Summers J, Mason WS,. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29 (2): 403-415
11. Summers J, Smolec JM, Snyder R,. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA 1978; 75 (9): 4533-4537
12. Marion PL, Oshiro LS, Regnery DC, Scullard GH, Robinson WS,. A virus in Beechey ground squirrels that is related to hepatitis B virus of humans. Proc Natl Acad Sci USA 1980; 77 (5): 2941-2945
13. Mason WS, Seal G, Summers J,. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol 1980; 36 (3): 829-836
14. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P,. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979; 281 (5733): 646-650
15. Liang TJ,. Hepatitis B: the virus and disease. Hepatology 2009; 5 (Suppl): S13-S21
16. Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM,. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013; 58 (4): 676-683
17. Le Bouvier GL,. Editorial: subtypes of hepatitis B antigen: clinical relevance? Ann Intern Med 1973; 79 (6): 894-896
18. Lin CL, Kao JH,. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 123-130
19. Chu CJ, Hussain M, Lok AS,. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122 (7): 1756-1762
20. Wai CT, Chu CJ, Hussain M, Lok AS,. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36 (6): 1425-1430
21. Kao JH, Chen PJ, Lai MY, Chen DS,. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118 (3): 554-559
22. Buster EH, Hansen BE, Lau GK, et al,. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137 (6): 2002-2009
23. Westland C, Delaney W, Yang H, et al,. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125 (1): 107-116
24. Magnius LO, Espmark JA,. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972; 109 (5): 1017-1021
25. Lok AS, Hadziyannis SJ, Weller IV, et al,. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25 (11): 1283-1287
26. Brunetto MR, Stemler M, Bonino F, et al,. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990; 10 (2): 258-261
27. Carman WF, Jacyna MR, Hadziyannis S, et al,. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2 (8663): 588-591
28. Chu CJ, Keeffe EB, Han SH, et al,. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38 (3): 619-628
29. Yang HI, Yeh SH, Chen PJ, et al,. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (16): 1134-1143
30. Yan H, Zhong G, Xu G, et al,. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049
31. Lee GC, Hwang LY, Beasley RP, Chen SH, Lee TY,. Immunogenicity of hepatitis B virus vaccine in healthy Chinese neonates. J Infect Dis 1983; 148 (3): 526-529
32. Szmuness W, Stevens CE, Harley EJ, et al,. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303 (15): 833-841
33. Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M,. Hepatitis B vaccine: immune responses in haemodialysis patients. Lancet 1980; 2 (8206): 1211-1213
34. WHO. Fact Sheets 2013. Available from: http: www.who.int/mediacentre/factsheets/fs378/en/ accessed June 10, 2015
35. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS,. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57 (4): 730-735
36. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ,. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310 (9): 974-976
37. Ott JJ, Stevens GA, Groeger J, Wiersma ST,. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30 (12): 2212-2219
38. Chen HL, Lee CN, Chang CH, et al,. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015; 62: 375
39. Sarkar M, Terrault NA,. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014; 60 (2): 448-451
40. Stevens CE, Beasley RP, Tsui J, Lee WC,. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292 (15): 771-774
41. Beasley RP, Hwang LY, Lin CC, et al,. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982; 146 (2): 198-204
42. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH,. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92 (6): 1844-1850
43. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB,. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94 (6): 744-748
44. Realdi G, Alberti A, Rugge M, et al,. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79 (2): 195-199
45. Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC,. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985; 5 (3): 431-434
46. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A,. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87 (17): 6599-6603
47. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662
48. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS,. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92 (6): 1839-1843
49. Sheen IS, Liaw YF, Tai DI, Chu CM,. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89 (4): 732-735
50. Lok AS, Lai CL,. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990; 10 (1): 29-34
51. Manno M, Camma C, Schepis F, et al,. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127 (3): 756-763
52. Bonino F, Rosina F, Rizzetto M, et al,. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90 (5 Pt 1): 1268-1273
53. Hadziyannis SJ, Vassilopoulos D,. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34 (4 Pt 1): 617-624
54. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF,. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009; 49 (6): 1859-1867
55. Brunetto MR, Oliveri F, Colombatto P, et al,. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139 (2): 483-490
56. Bertoletti A, Kennedy PT,. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol 2015; 12 (3): 258-263
57. Yuen MF, Wong DK, Fung J, et al,. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135 (4): 1192-1199
58. Chen YC, Sheen IS, Chu CM, Liaw YF,. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123 (4): 1084-1089
59. Chen CJ, Yang HI,. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26 (4): 628-638
60. Tseng TC, Liu CJ, Yang HC, et al,. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142 (5): 1140-1149 e3; quiz e13-4
61. Lee MH, Yang HI, Liu J, et al,. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013; 58 (2): 546-554
62. Chan HL, Thompson A, Martinot-Peignoux M, et al,. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011; 55 (5): 1121-1131
63. Sherman M, Kim RW, Dziura J,. Risk scores for hepatocellular carcinoma in chronic hepatitis B. Hepatology 2015; 61 (6): 1784-1786
64. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC,. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295 (10): 517-522
65. Perrillo RP, Schiff ER, Davis GL, et al,. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323 (5): 295-301
66. Lam KC, Lai CL, Trepo C, Wu PC,. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981; 304 (7): 380-386
67. Lok AS, Weller IV, Karayiannis P, et al,. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984; 4 (1): 45-49
68. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y,. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104 (4): 1116-1121
69. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-2695
70. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351 (12): 1206-1217
71. Belloni L, Allweiss L, Guerrieri F, et al,. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122 (2): 529-537
72. Lucifora J, Xia Y, Reisinger F, et al,. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343 (6176): 1221-1228
73. Lampertico P,. The royal wedding in chronic hepatitis B: the haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy. Hepatology 2015; 61 (5): 1459-1461
74. Konerman MA, Lok AS,. Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy? Clin Gastroenterol Hepatol 2015; 13 (2): 386-389
75. McKenzie R, Fried MW, Sallie R, et al,. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333 (17): 1099-1105
76. Lai CL, Chien RN, Leung NW, et al,. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339 (2): 61-68
77. Dienstag JL, Schiff ER, Wright TL, et al,. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341 (17): 1256-1263
78. Perrillo RP, Wright T, Rakela J, et al,. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33 (2): 424-432
79. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15): 1521-1531
80. Ling R, Mutimer D, Ahmed M, et al,. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24 (3): 711-713
81. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL,. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24 (3): 714-717
82. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348 (9): 800-807
83. Marcellin P, Chang TT, Lim SG, et al,. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348 (9): 808-816
84. Schiff ER, Lai CL, Hadziyannis S, et al,. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38 (6): 1419-1427
85. Fung SK, Andreone P, Han SH, et al,. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43 (6): 937-943
86. Lai CL, Gane E, Liaw YF, et al,. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357 (25): 2576-2588
87. Lai CL, Shouval D, Lok AS, et al,. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354 (10): 1011-1020
88. Chang TT, Gish RG, de Man R, et al,. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354 (10): 1001-1010
89. Marcellin P, Heathcote EJ, Buti M, et al,. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359 (23): 2442-2455
90. Tenney DJ, Rose RE, Baldick CJ, et al,. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49 (5): 1503-1514
91. Kitrinos KM, Corsa A, Liu Y, et al,. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59 (2): 434-442
92. Lok AS, Trinh H, Carosi G, et al,. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012; 143 (3): 619-628 e1
93. Chang TT, Liaw YF, Wu SS, et al,. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52 (3): 886-893
94. Marcellin P, Gane E, Buti M, et al,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865): 468-475
95. Kim WR, Terrault NA, Pedersen RA, et al,. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137 (5): 1680-1686
96. Chiang CJ, Yang YW, Chen JD, et al,. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology 2015; 61 (4): 1154-1162
97. Yapali S, Lok AS,. Does suppression of HBV replication by antiviral therapy confer the same benefit as host immune control of HBV? Gut 2014; 63 (12): 1833-1834